Watch More Highlights

Donna Kinzler, DNP, ACNP-BC, AOCNP, of the Allegheny Health Network Cancer Institute, discusses phase III findings from the PALLAS study of interest to advanced practitioners. The trial showed that adding 2 years of palbociclib to ongoing adjuvant endocrine therapy did not improve survival for patients with stage II to III hormone receptor–positive and HER2-negative early breast cancer (Abstract GS1-07).

Copyright © 2010-2021 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.